NIRF constitutes a nodal point in the cell cycle network and is a candidate tumor suppressor

Cell Cycle

Volumn 10, Issue 19, 2011, Pages 3284-3299

  Mori, Tsutomu ^a   Ikeda, Daisuke D ^b   Fukushima, Toshihiko ^a   Takenoshita, Seiichi ^a   Kochi, Hideo ^a,c  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Prefectural Hospitals Bureau   (Japan)

Author keywords

Cell cycle network; COPA; Glioblastoma; NIRF; Non small cell lung carcinoma; Rs719725; Systems biology; Tumor suppressor; Ubiquitin ligase; UHRF2

Indexed keywords

CYCLIN A2; CYCLIN B1; CYCLIN D1; CYCLIN E; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN LIGASE NIRF; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; COMPARATIVE GENOMIC HYBRIDIZATION; GENE DELETION; GENE EXPRESSION; HETEROZYGOSITY LOSS; HUMAN; LUNG NON SMALL CELL CANCER; PROTEIN INTERACTION; SINGLE NUCLEOTIDE POLYMORPHISM; UBIQUITINATION;

EID: 80053451766     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.19.17176     Document Type: Article

References (85)

1. 1 cell cycle control and cancer. Nature 2004; 432:298-306; PMID:15549091; DOI:10.1038/nature03094.
2. Albert R, Jeong H, Barabasi AL. Error and attack tolerance of complex networks. Nature 2000; 406:378-82; PMID:10935628; DOI:10.1038/35019019.
3. Barabási AL, Oltvai ZN. Network biology: understanding the cell's functional organization. Nat Rev Genet 2004; 5:101-13; PMID:14735121; DOI:10.1038/ nrg1272.
4. Jeong H, Mason SP, Barabasi AL, Oltvai ZN. Lethality and centrality in protein networks. Nature 2001; 411:41-2; PMID:11333967; DOI:10.1038/35075138.
5. Han JD, Bertin N, Hao T, Goldberg DS, Berriz GF, Zhang LV, et al. Evidence for dynamically organized modularity in the yeast protein-protein interaction network. Nature 2004; 430:88-93; PMID:15190252; DOI:10.1038/ nature02555.
6. Vidal M, Cusick ME, Barabasi AL. Interactome networks and human disease. Cell 2011; 144:986-98; PMID:21414488; DOI:10.1016/j.cell.2011.02.016.
7. Taylor IW, Linding R, Warde-Farley D, Liu Y, Pesquita C, Faria D, et al. Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat Biotechnol 2009; 27:199-204; PMID:19182785; DOI:10.1038/nbt.1522.
8. Wang YC, Chen BS. A network-based biomarker approach for molecular investigation and diagnosis of lung cancer. BMC Med Genomics 2011; 4:2; PMID:21211025; DOI:10.1186/1755-8794-4-2.
9. Zabel C, Sagi D, Kaindl AM, Steireif N, Klare Y, Mao L, et al. Comparative proteomics in neurodegenerative and non-neurodegenerative diseases suggest nodal point proteins in regulatory networking. J Proteome Res 2006; 5:1948-58; PMID:16889417; DOI:10.1021/pr0601077.
10. Bashir T, Pagano M. Aberrant ubiquitin-mediated proteolysis of cell cycle regulatory proteins and oncogenesis. Adv Cancer Res 2003; 88:101-44; PMID:12665054.
11. Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem 2001; 70:503-33; PMID:11395416; DOI:10.1146/annurev.biochem.70.1.503.
12. Vodermaier HC. APC/C and SCF: controlling each other and the cell cycle. Curr Biol 2004; 14:787-96; PMID:15380093; DOI:10.1016/j.cub.2004.09.020.
13. Lin DI, Barbash O, Kumar KG, Weber JD, Harper JW, Klein-Szanto AJ, et al. Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex. Mol Cell 2006; 24:355-66; PMID:17081987; DOI:10.1016/j.molcel.2006.09.007.
14. Okabe H, Lee SH, Phuchareon J, Albertson DG, McCormick F, Tetsu O. A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS ONE 2006; 1:128; PMID:17205132; DOI:10.1371/journal.pone. 0000128.
15. Santra MK, Wajapeyee N, Green MR. F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature 2009; 459:722-5; PMID:19412162; DOI:10.1038/nature08011.
16. Fbw7 ubiquitin ligase. Science 2001; 294:173-7; PMID:11533444; DOI:10.1126/science. 1065203.
17. Nakayama KI, Nakayama K. Ubiquitin ligases: cell cycle control and cancer. Nat Rev Cancer 2006; 6:369- 81; PMID:16633365; DOI:10.1038/nrc1881.
18. Kitagawa K, Kotake Y, Kitagawa M. Ubiquitinmediated control of oncogene and tumor suppressor gene products. Cancer Sci 2009; 100:1374-81; PMID:19459846; DOI:10.1111/j.1349-7006.2009.01196.x.
19. Mori T, Li Y, Hata H, Kochi H. NIRF is a ubiquitin ligase that is capable of ubiquitinating PCNP, a PEST-containing nuclear protein. FEBS Lett 2004; 557:209-14; PMID:14741369; DOI:10.1016/S0014- 5793(03)01495-9.
20. Li Y, Mori T, Hata H, Homma Y, Kochi H. NIRF induces G1 arrest and associates with Cdk2. Biochem Biophys Res Commun 2004; 319:464-8; PMID:15178429; DOI:10.1016/j.bbrc.2004.04.190.
21. Mori T, Li Y, Hata H, Ono K, Kochi H. NIRF, a novel RING finger protein, is involved in cell cycle regulation. Biochem Biophys Res Commun 2002; 296:530-6; PMID:12176013; DOI:10.1016/S0006-291X(02)00890-2.
22. Brandes U. A faster algorithm for betweenness centrality. J Math Sociol 2001; 25:163-77; DOI:10.1080/0022250X.2001.9990249.
23. Yu H, Kim PM, Sprecher E, Trifonov V, Gerstein M. The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics. PLOS Comput Biol 2007; 3:59; PMID:17447836; DOI:10.1371/journal.pcbi.0030059.
24. Gursoy A, Keskin O, Nussinov R. Topological properties of protein interaction networks from a structural perspective. Biochem Soc Trans 2008; 36:1398-403; PMID:19021563; DOI:10.1042/BST0361398.
25. Kocarnik JD, Hutter CM, Slattery ML, Berndt SI, Hsu L, Duggan DJ, et al. Characterization of 9p24 risk locus and colorectal adenoma and cancer: gene-environment interaction and meta-analysis. Cancer Epidemiol Biomarkers Prev 2010; 19:3131-9; PMID:20978172; DOI:10.1158/1055-9965.EPI-10-0878.
26. Ying H, Xiao ZX. Targeting retinoblastoma protein for degradation by proteasomes. Cell Cycle 2006; 5:506-8; PMID:16552188; DOI:10.4161/cc.5.5.2515.
27. Lee JT, Gu W. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ 2010; 17:86-92; PMID:19543236; DOI:10.1038/cdd.2009.77.
28. Inuzuka H, Fukushima H, Shaik S, Wei W. Novel insights into the molecular mechanisms governing Mdm2 ubiquitination and destruction. Oncotarget 2010; 1:685-90; PMID:21317463.
29. Lamothe B, Webster WK, Gopinathan A, Besse A, Campos AD, Darnay BG. TRAF6 ubiquitin ligase is essential for RANKL signaling and osteoclast differentiation. Biochem Biophys Res Commun 2007; 359:1044-9; PMID:17572386; DOI:10.1016/j. bbrc.2007.06.017.
30. Amemiya Y, Azmi P, Seth A. Autoubiquitination of BCA2 RING E3 ligase regulates its own stability and affects cell migration. Mol Cancer Res 2008; 6:1385-96; PMID:18819927; DOI:10.1158/1541-7786. MCR-08-0094.
31. Fujimori A, Matsuda Y, Takemoto Y, Hashimoto Y, Kubo E, Araki R, et al. Cloning and mapping of Np95 gene which encodes a novel nuclear protein associated with cell proliferation. Mamm Genome 1998; 9:1032-5; PMID:9880673; DOI:10.1007/s003359900920.
32. Hopfner R, Mousli M, Jeltsch JM, Voulgaris A, Lutz Y, Marin C, et al. ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIalpha expression. Cancer Res 2000; 60:121-8; PMID:10646863.
33. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, et al. Integration of biological networks and gene expression data using Cytoscape. Nat Protoc 2007; 2:2366-82; PMID:17947979; DOI:10.1038/nprot.2007.324.
34. Cerami EG, Gross BE, Demir E, Rodchenkov I, Babur O, Anwar N, et al. Pathway Commons, a web resource for biological pathway data. Nucleic Acids Res 2011; 39:685-90; PMID:21071392; DOI:10.1093/nar/gkq1039.
35. Legrain P, Selig L. Genome-wide protein interaction maps using two-hybrid systems. FEBS Lett 2000; 480:32-6; PMID:10967325; DOI:10.1016/S0014-5793(00) 01774-9.
36. Rigaut G, Shevchenko A, Rutz B, Wilm M, Mann M, Seraphin B. A generic protein purification method for protein complex characterization and proteome exploration. Nat Biotechnol 1999; 17:1030-2; PMID:10504710; DOI:10.1038/13732.
37. Sherr CJ. Principles of tumor suppression. Cell 2004; 116:235-46; PMID:14744434; DOI:10.1016/S0092-8674(03)01075-4.
38. Takeda DY, Wohlschlegel JA, Dutta A. A bipartite substrate recognition motif for cyclin-dependent kinases. J Biol Chem 2001; 276:1993-7; PMID:11067844; DOI:10.1074/jbc.M005719200.
39. Unoki M, Nishidate T, Nakamura Y. ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene 2004; 23:7601-10; PMID:15361834; DOI:10.1038/sj.onc.1208053.
40. Strogatz SH. Exploring complex networks. Nature 2001; 410:268-76; PMID:11258382; DOI:10.1038/35065725.
41. Stelzl U, Worm U, Lalowski M, Haenig C, Brembeck FH, Goehler H, et al. A human protein-protein interaction network: a resource for annotating the proteome. Cell 2005; 122:957-68; PMID:16169070; DOI:10.1016/j.cell.2005.08.029.
42. Maslov S, Sneppen K. Specificity and stability in topology of protein networks. Science 2002; 296:910-3; PMID:11988575; DOI:10.1126/science.1065103.
43. Wang J, Zhang S, Wang Y, Chen L, Zhang XS. Disease-aging network reveals significant roles of aging genes in connecting genetic diseases. PLOS Comput Biol 2009; 5:1000521; PMID:19779549; DOI:10.1371/journal. pcbi.1000521.
44. Newman MEJ. A measure of betweenness centrality based on random walks. Soc Networks 2005; 27:39-54; DOI:10.1016/j.socnet.2004.11.009.
45. Lee Y, Yang X, Huang Y, Fan H, Zhang Q, Wu Y, et al. Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. PLOS Comput Biol 2010; 6:1000730; PMID:20369013; DOI:10.1371/journal. pcbi.1000730.
46. Knuutila S, Aalto Y, Autio K, Bjorkqvist AM, El-Rifai W, Hemmer S, et al. DNA copy number losses in human neoplasms. Am J Pathol 1999; 155:683-94; PMID:10487825; DOI:10.1016/S0002- 9440(10)65166-8.
47. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, et al. Oncomine 3.0: genes, pathways and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007; 9:166-80; PMID:17356713; DOI:10.1593/neo.07112.
48. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455:1061-8; PMID:18772890; DOI:10.1038/nature07385.
49. MacDonald JW, Ghosh D. COPA - cancer outlier profile analysis. Bioinformatics 2006; 22:2950- 1; PMID:16895932; DOI:10.1093/bioinformatics/ btl433.
50. Ghosh D, Chinnaiyan AM. Genomic outlier profile analysis: mixture models, null hypotheses and nonparametric estimation. Biostatistics 2009; 10:60-9; PMID:18539648; DOI:10.1093/biostatistics/kxn015.
51. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007; 450:893-8; PMID:17982442; DOI:10.1038/nature06358.
52. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA 2007; 104:20007-12; PMID:18077431; DOI:10.1073/pnas.0710052104.
53. Kotliarov Y, Steed ME, Christopher N, Walling J, Su Q, Center A, et al. High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances. Cancer Res 2006; 66:9428-36; PMID:17018597; DOI:10.1158/0008-5472.CAN-06-1691.
54. Haverty PM, Fridlyand J, Li L, Getz G, Beroukhim R, Lohr S, et al. High-resolution genomic and expression analyses of copy number alterations in breast tumors. Genes Chromosomes Cancer 2008; 47:530- 42; PMID:18335499; DOI:10.1002/gcc.20558.
55. Collins FS, Barker AD. Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. Sci Am 2007; 296:50-7; PMID:17348159; DOI:10.1038/ scientificamerican0307- 50.
56. Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, et al. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 2009; 69:4674-81; PMID:19470766; DOI:10.1158/0008-5472.CAN-09-0146.
57. Gunnarsson R, Isaksson A, Mansouri M, Goransson H, Jansson M, Cahill N, et al. Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients. Leukemia 2010; 24:211-5; PMID:19741724; DOI:10.1038/leu.2009.187.
58. Lu X, Zhang K, van Sant C, Coon J, Semizarov D. An algorithm for classifying tumors based on genomic aberrations and selecting representative tumor models. BMC Med Genomics 2010; 3:23; PMID:20569491; DOI:10.1186/1755-8794- 3-23.
59. Sos ML, Michel K, Zander T, Weiss J, Frommolt P, Peifer M, et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 2009; 119:1727-40; PMID:19451690; DOI:10.1172/JCI37127.
60. Sarkar S, Roy BC, Hatano N, Aoyagi T, Gohji K, Kiyama R. A novel ankyrin repeat-containing gene (Kank) located at 9p24 is a growth suppressor of renal cell carcinoma. J Biol Chem 2002; 277:36585-91; PMID:12133830; DOI:10.1074/jbc.M204244200.
61. Gunduz E, Gunduz M, Ali MA, Beder L, Tamamura R, Katase N, et al. Loss of heterozygosity at the 9p21-24 region and identification of BRM as a candidate tumor suppressor gene in head and neck squamous cell carcinoma. Cancer Invest 2009; 27:661-8; PMID:19488910; DOI:10.1080/07357900802563010.
62. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding and treatment strategies. J Clin Oncol 2011; 29:573-82; PMID:21220604; DOI:10.1200/ JCO.2010.29.8711.
63. Kounalakis N, Goydos JS. Tumor cell and circulating markers in melanoma: diagnosis, prognosis and management. Curr Oncol Rep 2005; 7:377-82; PMID:16091200; DOI:10.1007/s11912-005-0065-2.
64. Cao Q, Chen J, Zhu L, Liu Y, Zhou Z, Sha J, et al. A testis-specific and testis developmentally regulated tumor protein D52 (TPD52)-like protein TPD52L3/hD55 interacts with TPD52 family proteins. Biochem Biophys Res Commun 2006; 344:798-806; PMID:16631610; DOI:10.1016/j.bbrc.2006.03.208.
65. Yang ZQ, Imoto I, Fukuda Y, Pimkhaokham A, Shimada Y, Imamura M, et al. Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines. Cancer Res 2000; 60:4735-9; PMID:10987278.
66. Sato M, Takahashi K, Nagayama K, Arai Y, Ito N, Okada M, et al. Identification of chromosome arm 9p as the most frequent target of homozygous deletions in lung cancer. Genes Chromosomes Cancer 2005; 44:405-14; PMID:16114034; DOI:10.1002/gcc.20253.
67. Smith-Sørensen B, Hovig E. CDKN2A (p16INK4A) somatic and germline mutations. Hum Mutat 1996; 7:294-303; PMID:8723678; DOI:10.1002/(SICI)1098- 1004(1996)7:4 〈294::AID-HUMU2〉3.0.CO;2-9.
68. Murai R, Yoshida Y, Muraguchi T, Nishimoto E, Morioka Y, Kitayama H, et al. A novel screen using the Reck tumor suppressor gene promoter detects both conventional and metastasis-suppressing anticancer drugs. Oncotarget 2010; 1:252-64; PMID:21304177.
69. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463:899-905; PMID:20164920; DOI:10.1038/nature08822.
70. Talbot SG, Estilo C, Maghami E, Sarkaria IS, Pham DK, Oc P, et al. Gene expression profiling allows distinction between primary and metastatic squamous cell carcinomas in the lung. Cancer Res 2005; 65:3063-71; PMID:15833835.
71. Barrett T, Edgar R. Gene expression omnibus: microarray data storage, submission, retrieval and analysis. Methods Enzymol 2006; 411:352-69; PMID:16939800; DOI:10.1016/S0076- 6879(06)11019-8.
72. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011; 12:56-68; PMID:21164525; DOI:10.1038/nrg2918.
73. Xu J, Li Y. Discovering disease-genes by topological features in human protein-protein interaction network. Bioinformatics 2006; 22:2800-5; PMID:16954137; DOI:10.1093/bioinformatics/btl467.
74. Yu H, Braun P, Yildirim MA, Lemmens I, Venkatesan K, Sahalie J, et al. High-quality binary protein interaction map of the yeast interactome network. Science 2008; 322:104-10; PMID:18719252; DOI:10.1126/science.1158684.
75. Goh KI, Oh E, Kahng B, Kim D. Betweenness centrality correlation in social networks. Phys Rev E Stat Nonlin Soft Matter Phys 2003; 67:17101; PMID:12636633; DOI:10.1103/PhysRevE.67.017101.
76. Akakura S, Nochajski P, Gao L, Sotomayor P, Matsui S, Gelman IH. Rb-dependent cellular senescence, multi-nucleation and susceptibility to oncogenic transformation through PKC scaffolding by SSeCKS/AKAP12. Cell Cycle 2010; 9:4656-65; PMID:21099353; DOI:10.4161/cc.9.23.13974.
77. Lu Z, Hunter T. Degradation of activated protein kinases by ubiquitination. Annu Rev Biochem 2009; 78:435-75; PMID:19489726; DOI:10.1146/annurev. biochem.013008.092711.
78. Kastan MB, Bartek J. Cell cycle checkpoints and cancer. Nature 2004; 432:316-23; PMID:15549093; DOI:10.1038/nature03097.
79. Sharif J, Muto M, Takebayashi S, Suetake I, Iwamatsu A, Endo TA, et al. The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature 2007; 450:908-12; PMID:17994007; DOI:10.1038/nature06397.
80. Noonan EJ, Place RF, Basak S, Pookot D, Li LC. miR-449a causes Rb-dependent cell cycle arrest and senescence in prostate cancer cells. Oncotarget 2010; 1:349-58; PMID:20948989.
81. Hatakeyama M, Weinberg RA. The role of RB in cell cycle control. Prog Cell Cycle Res 1995; 1:9-19; PMID:9552350; DOI:10.1007/978-1-4615-1809-9-2.
82. Assenov Y, Ramirez F, Schelhorn SE, Lengauer T, Albrecht M. Computing topological parameters of biological networks. Bioinformatics 2008; 24:282- 4; PMID:18006545; DOI:10.1093/bioinformatics/btm554.
83. Akavia UD, Litvin O, Kim J, Sanchez-Garcia F, Kotliar D, Causton HC, et al. An integrated approach to uncover drivers of cancer. Cell 2010; 143:1005-17; PMID:21129771; DOI:10.1016/j.cell.2010.11.013.
84. Wu B. Cancer outlier differential gene expression detection. Biostatistics 2007; 8:566-75; PMID:17021278; DOI:10.1093/biostatistics/kxl029.
85. Pekarsky Y, Croce CM. Is miR-29 an oncogene or tumor suppressor in CLL? Oncotarget 2010; 1:224-7; PMID:20936047.